Sommer, Kelsey N. http://orcid.org/0000-0002-8431-0174
Bhurwani, Mohammad Mahdi Shiraz
Tutino, Vincent
Siddiqui, Adnan
Davies, Jason
Snyder, Kenneth
Levy, Elad
Mokin, Maxim
Ionita, Ciprian N.
Funding for this research was provided by:
national institutes of health (R21 NS109575-01)
Article History
Received: 9 July 2021
Accepted: 11 September 2021
First Online: 27 September 2021
Declarations
:
: The protocol for collection and the data analysis was approved by the Institutional Review Board (IRB) at the University at Buffalo. Informed consent was obtained from all human participants.
: Not applicable.
: <i>KNS</i> – Shareholder: QAS.AI.<i>MMSB</i> – Shareholder: QAS.AI.<i>VT</i> – Principal investigator: National Science Foundation Award No. 1746694 and NIH NINDS award R43 NS115314–0. Awardee of a Clinical and Translational Science Institute grant, a Cummings Foundation grant, and grants from the Brain Aneurysm Foundation. Co-founder: Neurovascular Diagnostics, Inc. Shareholder: QAS.AI.<i>AS</i> – Research grant: NIH/NINDS 1R01NS091075 as a co-investigator for “Virtual Intervention of Intracranial Aneurysms”. Financial interest/investor/stock options/ownership: Amnis Therapeutics, Apama Medical, Blink TBI Inc., Buffalo Technology Partners Inc., Cardinal Consultants, Cerebrotech Medical Systems, Inc. Cognition Medical, Endostream Medical Ltd., Imperative Care, International Medical Distribution Partners, Neurovascular Diagnostics Inc., Q’Apel Medical Inc., Rebound Therapeutics Corp., Rist Neurovascular Inc., Serenity Medical Inc., Silk Road Medical, StimMed, Synchron, Three Rivers Medical Inc., Viseon Spine Inc. Consultant/advisory board: Amnis Therapeutics, Boston Scientific, Canon Medical Systems USA Inc., Cerebrotech Medical Systems Inc., Cerenovus, Corindus Inc., Endostream Medical Ltd., Guidepoint Global Consulting, Imperative Care, Integra LifeSciences Corp., Medtronic, MicroVention, Northwest University–DSMB Chair for HEAT Trial, Penumbra, Q’Apel Medical Inc., Rapid Medical, Rebound Therapeutics Corp., Serenity Medical Inc., Silk Road Medical, StimMed, Stryker, Three Rivers Medical, Inc., VasSol, W.L. Gore & Associates. Principal investigator/steering comment of the following trials: Cerenovus LARGE and ARISE II; Medtronic SWIFT PRIME and SWIFT DIRECT; MicroVention FRED & CONFIDENCE; MUSC POSITIVE; and Penumbra 3D Separator, COMPASS, and INVEST. Shareholder: QAS.AI.<i>JD</i> – Research grant: National Center for Advancing Translational Sciences of the National Institutes of Health under award number KL2TR001413 to the University at Buffalo. Speakers’ bureau: Penumbra; Honoraria: Neurotrauma Science, LLC. Shareholder/ownership interests: RIST Neurovascular. Shareholder: QAS.AI.<i>KS</i> – Consulting and teaching for Canon Medical Systems Corporation, Penumbra Inc., Medtronic, and Jacobs Institute. Co-Founder: Neurovascular Diagnostics, Inc. Shareholder: QAS.AI.<i>EL</i> – shareholder/Ownership interests: NeXtGen Biologics, RAPID Medical, Claret Medical, Cognition Medical, Imperative Care (formerly the Stroke Project), Rebound Therapeutics, StimMed, Three Rivers Medical. National Principal Investigator/Steering, QAS.AI.Committees: Medtronic (merged with Covidien Neurovascular) SWIFT Prime and SWIFT Direct Trials. Honoraria: Medtronic (training and lectures). Consultant: Claret Medical, GLG Consulting, Guidepoint Global, Imperative Care, Medtronic, Rebound, StimMed. Advisory Board: Stryker (AIS Clinical Advisory Board), NeXtGen Biologics, MEDX, Cognition Medical, Endostream Medical. Site Principal Investigator: CONFIDENCE study (MicroVention), STRATIS Study—Sub I (Medtronic).<i>MM</i> – Grants: Principal investigator NIH R21NS109575 Consultant: Medtronic, Cerenovus. Stock options: Serenity medical, Synchron, Endostream, VICIS, shareholder QAS.AI.<i>CI</i> – Equipment grant from Canon Medical Systems, support from the Cummings Foundation, NIH R21 grant, shareholder QAS.AI.